Clinical and Laboratory Predictors of Mortality in Hospitalized COVID-19 Patients

IRCMJ logo
PDF
HTML

Keywords

COVID-19
Epidemiology
Intensive care unit
Laboratory
Mortality

How to Cite

Riahi T., ShokriS., Faiz S. H. R., Hemati K., MousavieS. H., BaghestaniA., KhazaeianA., & HassanloueiB. (2021). Clinical and Laboratory Predictors of Mortality in Hospitalized COVID-19 Patients. Iranian Red Crescent Medical Journal, 23(5). Retrieved from https://ircmj.com/index.php/IRCMJ/article/view/531

Abstract

Background: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a variety of symptoms and laboratory and radiologic features whose identification can help diagnose and manage patients with COVID-19 more effectively.

Objectives: This study aimed to describe the epidemiological, clinical, and laboratory features of patients with COVID-19, compare clinical features of patients in the intensive care unit (ICU) with those of non-ICU admitted patients, and define mortality risk factors for this disease.

Methods: This cross-sectional study was carried out on 781 COVID-19 patients hospitalized in Rasool Akram Medical Complex, Tehran, Iran, from February to May 2020. Patients’ epidemiological, demographic, clinical, laboratory findings were collected. Routine blood tests included complete blood count, coagulation profile, and serum biochemical tests. Confirmed infection was defined as positive reverse transcription-polymerase chain reaction (RT-PCR) to SARS-CoV-2 in their nasopharyngeal specimens or typical clinical, laboratory, and imaging findings of COVID-19 infection altogether. All data were analyzed using SPSS software (version 21).

Results: In this study, the majority of patients were male (n=470, 60.2%) and the remainder were female. The median age of the patients was 64 years. Hypertension (31.8%) and tuberculosis (1.4%) were the most common and the least common  underlying condition among the patients, respectively. Moreover, cough and seizure were the most common (75.7%) and the least common (2.4%) symptoms in patients. The history of diabetes mellitus, the presence of dyspnea, loss of taste, and the occurrence of seizure were associated with a higher risk of ICU admission. On the other hand, advanced age, positive PCR, presence of dyspnea, myalgia, loss of taste, and elevated liver enzymes, and lactate dehydrogenase (LDH) were associated with a higher risk of mortality. Based on the results, smoking had a preventive effect on mortality (OR=0.292, P=0.048); however, it had no significant effect on ICU admission.

Conclusion: According to the obtained results, positive PCR and initial symptoms of dyspnea and myalgia were associated with increased odds of mortality by two times. In addition, elevated alanine aminotransferase and lactate dehydrogenase were associated with a higher rate of mortality. ICU admission was the main variable to increase the odds of mortality. Eventually, smoking might play a protective role against COVID-19 mortality.

PDF
HTML

References

  1. Huang[S1]  C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/ S0140-6736(20)30183-5. [PubMed: 31986264].
  2. Faiz SH, Riahi T, Rahimzadeh P, Nikoubakht N. Commentary: remote electronic consultation for COVID-19 patients in teaching hospitals in Tehran, Iran. Med J Islam Repub Iran. 2020;34(1):31. doi: 10.34171/mjiri.34.31. [PubMed: 32617270].
  3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi: 10.1056/NEJMoa2002032. [PubMed: 32109013].
  4. Daneshfar M, Dadashzadeh N, Ahmadpour M, RagatiHaghi H, Rahmani V, Forouzesh M, et al. Lessons of mortality following COVID-19 epidemic in the United States especially in the geriatrics. J Nephropharmacol. 2021;10(1):e06. doi: 10.34172/npj.2021.06.
  5. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARSCoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. DOI: 10.1016/S2213-2600(20)30079-5. [PubMed: 32105632].
  6. Forouzesh M, Rahimi A, Valizadeh R, Dadashzadeh N, Mirzazadeh A. Clinical display, diagnostics and genetic implication of novel Coronavirus (COVID-19) epidemic. Eur Rev Med Pharmacol Sci. 2020;24(8):4607-15. doi: 10.26355/eurrev_202004_21047. [PubMed: 32374001].
  7. Lotfi B, Farshid S, Dadashzadeh N, Valizadeh R, Rahimi MM. Is coronavirus disease 2019 (COVID-19) associated with renal involvement? A review of century infection. Jundishapur J Microbiol. 2020;13(4):e102899. doi: 10.5812/jjm.102899.
  8. Valizadeh R, Dadashzadeh N, Zakeri R, James Kelllner S, Rahimi MM. Drug therapy in hospitalized patients with very severe symptoms following COVID-19. J Nephropharmacol. 2020;9(2):e21. doi: 10.34172/ipp.2020.16.
  9. World Health Organization. Coronavirus disease 2019 (COVID-19) outbreak. Geneva: World Health Organization; 2020.
  10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/ S0140-6736(20)30183-5. [PubMed: 31986264].
  11. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-90. doi: 10.1001/jamaneurol.2020.1127. [PubMed: 32275288].
  12. Lovato A, de Filippis C, Marioni G. Upper airway symptoms in coronavirus disease 2019 (COVID-19). Am J Otolaryngol. 2020;41(3):102474. doi: 10.1016/j.amjoto.2020.102474. [PubMed: 32278470].
  13. Lovato A, de Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020;99(9):569-76. doi: 10.1177/0145561320920762. [PubMed: 32283980].
  14. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. [PubMed: 32064853].
  15. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. doi: 10.1136/bmj.m606. [PubMed: 32075786].
  16. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (‎‎‎‎nCoV)‎‎‎‎ infection is suspected: interim guidance, 25 January 2020. Geneva: World Health Organization; 2020.
  17. SamimiArdestani SH, MohammadiArdehali M, Rabbani Anari M, Rahmaty B, Erfanian R, Akbari M, et al. The coronavirus disease 2019: the prevalence, prognosis, and recovery from olfactory dysfunction (OD). Acta Otolaryngol. 2020;141(2):171-80. doi: 10.1080/00016489.2020.1836397. [PubMed: 33176530].
  18. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. doi: 10.1016/j.tmaid.2020.101623. [PubMed: 32179124].
  19. Jin X, Lian J, Hu J, Gao J, Zheng L, Zhang Y, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002-9. doi: 10.1136/gutjnl-2020-320926. [PubMed: 32213556].
  20. Besharat S, Alamdari NM, Dadashzadeh N, Talaie R, Mousavi SS, Barzegar A, et al. Clinical and demographic characteristics of patients with COVID-19 who died in Modarres Hospital. Open Access Maced J Med Sci. 2020;8(T1):144-9. doi: 10.3889/oamjms.2020.5013.
  21. Nasimfar A, Valizadeh R, Nanbakhsh M. Do we trust the polymerase chain reaction test result in children to diagnose COVID-19? A case report of COVID-19. Open Access Maced J Med Sci. 2020;8(T1):32-5. doi: 10.3889/oamjms.2020.4742.
  22. Barzegar A, Ghadipasha G, Rezaei N, Forouzesh M, Valizadeh R. New hope for treatment of respiratory involvement following COVID-19 by bromhexine. J Nephropharmacol. 2021;10(2):e11. doi: 10.34172/npj.2021.11.
  23. Rahimi MM, Jahantabi E, Lotfi B, Forouzesh M, Valizadeh R, Farshid S. Renal and liver injury following the treatment of COVID-19 by remdesivir. J Nephropathol. 2021;10(2):e10. doi: 10.34172/jnp.2021.10.
  24. Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res. 2020;22(9):1653-6. doi: 10.1093/ntr/ntaa082. [PubMed: 32399563].
  25. Magfira N, Helda H. Correlation between adult tobacco smoking prevalence and mortality of coronavirus disease-19 across the world. Acta Med Indones. 2020;52(4):318-25. [PubMed: 33377876].
  26. Wan S, Xiang Y, Fang W. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92(7):797-806. doi: 10.1002/jmv.25783. [PubMed: 32198776].
  27. Zaami S, Marinelli E, Varì MR. New trends of substance abuse during COVID-19 pandemic: an international perspective. Front Psychiatry. 2020;11:700. doi: 10.3389/fpsyt.2020.00700. [PubMed: 32765328].
  28. Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020;173(1):61–2. DOI: 10.7326/M20-1212. [PubMed: 32240293].
  29. Sy KTL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect Dis (Lond). 2020;52(12):902-7. doi: 10.1080/23744235.2020.1806353. [PubMed: 32808838].